Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02197 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Clover Biopharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clover Biopharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clover Biopharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Clover Biopharmaceuticals's Days Payable falls into.
Clover Biopharmaceuticals Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Clover Biopharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clover Biopharmaceuticals (HKSE:02197) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Clover Biopharmaceuticals and its competitors. Over the past decade, Clover Biopharmaceuticals' Days Payable has ranged from 4,056.53 to 53,758.77. According to the industry distribution chart, Clover Biopharmaceuticals ranks #17 out of 704 companies in the Biotechnology industry, placing it in the top 2.4%.
Is Clover Biopharmaceuticals' Days Payable too high?
Clover Biopharmaceuticals' current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 4,056.53 to a high of 53,758.77. Based on the distribution chart, Clover Biopharmaceuticals ranks #17 out of 704 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clover Biopharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Clover Biopharmaceuticals' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clover Biopharmaceuticals ranks #17 out of 704 companies for Days Payable. This places Clover Biopharmaceuticals in the top 2% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.72. Historically, Clover Biopharmaceuticals' own Days Payable has ranged from 4,056.53 to 53,758.77 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.72, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Clover Biopharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 112.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clover Biopharmaceuticals's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clover Biopharmaceuticals stock overvalued right now?
Clover Biopharmaceuticals (HKSE:02197) has a current Days Payable of 0.00. The current Days Payable is 0.00. Clover Biopharmaceuticals' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Clover Biopharmaceuticals (HKSE:02197), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clover Biopharmaceuticals Ltd is a clinical-stage biotechnology company committed to unleashing the power of vaccines to save lives and improve health around the world. The leverage the proprietary Trimer-Tag technology platform to conduct R&D for vaccines that can fulfill unmet needs, with a focus on building a respiratory vaccine franchise to reduce the burden of vaccine-preventable diseases. The Group has only one operating segment, which is the research and development, manufacturing, and commercialisation of vaccines. Geographically, the company earns revenue from Mainland China and Korea.
28GF Score
Get the complete analysis for HKSE:02197
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02197 has been successfully added to your 
